Official TitleBeiGene: Next-Day Disclosure Report Filed
More from this company
BRUKINSA Achieves 74% 6-Year PFS in Treatment-Naïve CLL
BRUKINSA Demonstrates Strong 6-Year PFS in Treatment-Naïve CLL Patients
BeOne Medicines Reports Q4 Revenue of $1.2B, FY Revenue Hits $4.5B
BeOne Medicines Reports Q4 and FY 2025 Financials, Highlighting BRUKINSA Success
BeiGene reported $5.3 billion in revenue for 2025, a 40% year-over-year increase, and projected 2026 revenue between $6.2 billion and $6.4 billion, signaling sustained growth.
BeiGene Reports 40% Revenue Growth in 2025, Projecting Up to $6.4 Billion in 2026